Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase I Pipeline Programs

First-in-human and early clinical safety studies in Phase I.

Programs 4,713
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.

Top sponsors

Pipeline programs

Page 57 of 99

  1. MK-4830-001

    Merck Sharp and Dohme

    Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD-1-exposed Advanced/Met HNSCC, Advanced/Met HNSCC, Advanced/Met NSCLC, Advance/Met RCC, Advanced/Met Gastric or GEJ adenocarcinoma, Ovarian Cancer. TNBC, Advanced Mesothelioma, Advanced Solid tumors(coformulation)

    phase 1 other active

    1 trial

  2. MK-7091 Formulations Study in Healthy Adult Participants

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 1 other active

    1 trial

  3. MK-7480 Multiple Ascending Dose Study in Healthy Participants

    Merck Sharp and Dohme

    Non-alcoholic steatohepatitis

    phase 1 other active

    1 trial

  4. MK-8294-001

    Merck Sharp and Dohme

    Breast Cancer, Cervical squamous cell carcinoma, Endometrial Carcinoma, Esophageal squamous cell carcinoma, Head and neck squamous cell carcinoma, Bladder Cancer

    phase 1 other active

    1 trial

  5. MKC-1

    CASI Pharmaceuticals

    Hematological Malignancies

    phase 1 small molecule completed

    1 trial

  6. MLN0128

    Takeda

    Advanced Solid Malignancies

    phase 1 small molecule completed

    2 trials

  7. MLN0264

    Takeda

    Advanced Gastrointestinal Malignancies

    phase 1 small molecule completed

    1 trial

  8. MLN0264

    Takeda

    Advanced Gastrointestinal Carcinoma

    phase 1 small molecule terminated

    1 trial

  9. MLN1117

    Takeda

    Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma

    phase 1 small molecule terminated

    1 trial

  10. MLN1202

    Takeda

    Healthy Japanese and Caucasian Male Adults

    phase 1 small molecule terminated

    1 trial

  11. MLN2480

    Takeda

    Melanoma

    phase 1 small molecule completed

    1 trial

  12. MLN2480

    Takeda

    Advanced Nonhematologic Malignancies

    phase 1 small molecule completed

    1 trial

  13. MLN3126

    Takeda

    Healthy Volunteers

    phase 1 small molecule terminated

    1 trial

  14. MLN3126

    Takeda

    Safety

    phase 1 small molecule terminated

    1 trial

  15. MLN4924

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  16. MLN4924

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  17. MLN4924

    Takeda

    Acute Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  18. MLN7243

    Takeda

    Advanced Malignant Solid Tumors

    phase 1 small molecule terminated

    1 trial

  19. MMV390048 40 mg

    CNS Pharmaceuticals

    Malaria

    phase 1 small molecule completed

    1 trial

  20. MNPR-101-DFO*-89Zr

    Monopar Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  21. MNPR-101-PCTA-177Lu

    Monopar Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  22. MOR106

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule terminated

    1 trial

  23. MOR106 single ascending doses, intravenous

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  24. MP-101-02

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD)

    phase 1 other active

    1 trial

  25. MP-424 (Telaprevir)

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial

  26. MPT0B640

    INTENSITY THERAPEUTICS, INC.

    Covid19

    phase 1 small molecule terminated

    1 trial

  27. MPT0B640

    INTENSITY THERAPEUTICS, INC.

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  28. MRG007

    ArriVent BioPharma

    Locally Advanced or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

  29. MRT-6160

    Monte Rosa Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  30. MRT-8102

    Monte Rosa Therapeutics

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  31. MRx-4DP0004

    4D Molecular Therapeutics

    Asthma

    phase 1 small molecule terminated

    1 trial

  32. MRx0029

    4D Molecular Therapeutics

    Idiopathic Parkinson Disease

    phase 1 mab terminated

    1 trial

  33. MRx0518

    4D Molecular Therapeutics

    Pancreatic Cancer

    phase 1 small molecule terminated

    1 trial

  34. MRx0518 Capsules

    4D Molecular Therapeutics

    Melanoma

    phase 1 small molecule active

    1 trial

  35. MS100070_0087

    Merck Sharp and Dohme

    Central Nervous System Tumors

    phase 1 small molecule active

    1 trial

  36. MS200569_0065

    Merck Sharp and Dohme

    Healthy

    phase 1 other active

    1 trial

  37. MS201924_0001

    Merck Sharp and Dohme

    Metastatic or Locally Advanced Unresectable Solid Tumors

    phase 1 other active

    1 trial

  38. MS201924_0003

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  39. MS202359_0025

    Merck Sharp and Dohme

    Locally Advanced Squamous Cell Carcinoma of the Head and Neck

    phase 1 other active

    1 trial

  40. MS202650_0001

    Merck Sharp and Dohme

    Advanced solid tumors and colorectal cancer

    phase 1 other active

    1 trial

  41. MS700623_0061

    Merck Sharp and Dohme

    Infertility

    phase 1 other active

    1 trial

  42. MSB11455

    Fresenius Kabi Australia Pty Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  43. MSB11456

    Fresenius Kabi Australia Pty Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  44. MSC-derived exosomes

    Regeneron Ireland Designated Activity Company (DAC)

    Long COVID-19 Syndrome

    phase 1 mab active

    1 trial

  45. MSC2156119J

    Merck KGaA, Darmstadt, Germany

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  46. MSCs

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 1 mab active

    1 trial

  47. MSCs-derived exosomes

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Coronavirus

    phase 1 mab completed

    1 trial

  48. MSD-001

    Lxo Ireland Designated Activity Company

    Mental Health Disorders

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many Phase I pipeline programs are in the directory?

4,713 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.